Cancer Institute A national cancer institute
designated cancer center

Michael Link

Publication Details

  • A STUDY OF TOXICITY AND COMPARATIVE THERAPEUTIC EFFICACY OF VINDESINE-PREDNISONE VS VINCRISTINE-PREDNISONE IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA IN RELAPSE - A PEDIATRIC ONCOLOGY GROUP-STUDY INVESTIGATIONAL NEW DRUGS Vats, T., Buchanan, G., Mehta, P., Ragab, A., HVIZDALE, E., Nitschke, R., Link, M., Beardsley, G. P., MAYBEE, D., Krischer, J. 1992; 10 (3): 231-234

    Abstract:

    Vindesine (des-acetyl Vinblastine) is a synthetic derivative of vinblastine, and was produced with the hope that it would have less neurotoxicity and hematopoietic toxicity than other vinca alkaloids. Phase I and II studies also demonstrated significant activity in lymphoid malignancies, especially Acute Lymphoblastic Leukemia (ALL). The present study was designed to compare therapeutic effectiveness of twice weekly vindesine (2 mg/M2/dose) plus Prednisone (60 mg/M2/dose) (Treatment 1) to weekly Vincristine (2 mg/M2/dose) plus Prednisone (60 mg/M2/day) (Treatment 2). All patients were less than 21 years of age, and had documented bone marrow relapse (blast count > 25%). In 39 patients presumed sensitive to vincristine, there were 11 complete responses out of 20 patients (55%) randomized to receive vindesine/prednisone and 7 complete responses out of 19 patients (37%) treated with Vincristine/Prednisone. In 37 patients resistant to vincristine, there were 7 complete responses (19%). Vindesine was more toxic than Vincristine. Major toxicities of vindesine included paraesthesias, peripheral neuropathy and ileus. Vindesine hematological toxicity appeared greater, but such toxicity is hard to assess in patients with bone marrow disease. In this study, vindesine and vincristine had similar efficacy, but vindesine use was associated with more toxicity.

    View details for Web of Science ID A1992JX01000015

    View details for PubMedID 1428733

Stanford Medicine Resources:

Footer Links: